Events & Presentations
Upcoming Events
May 31 - Jun 04, 2024
Abstract Selected for Late-Breaking Oral Presentation
- June 3, 2024 | 8:00 AM - 9:30 AM CT
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer
Abstracts Selected for Poster Presentation
- June 2, 2024 | 9:00 AM - 12:00 PM CT
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
Abstract: 6124 | Poster Session - Head and Neck Cancer - June 3, 2024 | 9:00 AM - 12:00 PM CT
A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
Abstract 5623 | Poster Session - Gynecologic Cancer
Chicago, Illinois
Past Events
Apr 09 - Apr 11, 2024
Helen Sabzevari, PhD, President and CEO of Precigen, to participate in two events at the 2024 Alliance for Regenerative Medicine Cell and Gene Meeting on the Med. She will participate as a panelist on a panel titled "A Forecast on the 2024 CGTx Landscape" on Tuesday, April 9, 2024 at 5:15 PM CET and provide a company presentation on Wednesday, April 10, 2024 at 2:30 PM CET.
Rome, Italy
Mar 25, 2024 at 1:00 PM EDT
Hosted by Jennifer Kim, Biotechnology Analyst at Cantor Fitzgerald, the virtual fireside chat will include discussion of the investigational PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). Participants will include Helen Sabzevari, PhD, President and CEO of Precigen, and Clint T. Allen, MD, Principal Investigator, Section on Translational Tumor Immunology at the National Institutes of Health (NIH), and a lead investigator for the PRGN-2012 clinical study. The call is available to institutional clients of Cantor Fitzgerald.
Mar 19, 2024 at 4:30 PM EDT
Precigen full year 2023 financial results general business updates.
Mar 13 - Mar 16, 2024
Precigen participated in the Eurogin International Multidisciplinary HPV Congress taking place March 13-16 in Stockholm, Sweden.
Stockholm, Sweden
Feb 13, 2024
at 3:20 PM - 3:50 PM EST
Helen Sabzevari, PhD, President and CEO of Precigen, provided a company presentation.
Jan 10, 2024 at 5:15 PM PST
Helen Sabzevari, PhD, President and CEO of Precigen, presented a corporate and clinical overview at the 42nd Annual J.P. Morgan Healthcare Conference.
Dec 06, 2023 at 3:00 PM EST
Helen Sabzevari, PhD, President and CEO, Precigen, participated in a fireside chat on Wednesday, December 6 at 3:00 PM ET at the JMP Securities Hematology and Oncology Summit.
Nov 15, 2023
at 10:55 AM - 11:25 AM EST
Helen Sabzevari, PhD, President and CEO, Precigen, presented a company overview at the Stifel 2023 Healthcare Conference on November 14-15, 2023 in New York.
New York, NY
Nov 09, 2023
at 12:00 PM - 1:00 PM EST
Helen Sabzevari, PhD, President and CEO, Precigen, participated as a panelist in the Endpoints Webinar discussion on the State of the Union for Advanced Therapies.
Oct 26, 2023 at 2:00 PM EDT
Helen Sabzevari, PhD, President and CEO, Precigen, participated in an Acute Myeloid Leukemia (AML) panel discussion on Thursday, October 26.
Virtual
Oct 24, 2023
at 5:00 PM - 7:00 PM CEST
Dr. Scott M. Norberg, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, presented an abstract titled, "Significant clinical benefit and enhanced T-cell responses with repeated administration of PRGN-2012, a novel gorilla adenoviral vector based immunotherapy, in adult patients with severe Recurrent Respiratory Papillomatosis.
Brussels, Belgium
Oct 11, 2023 at 3:30 PM PDT
Helen Sabzevari, PhD, President and CEO, Precigen, provided a company presentation on Wednesday, October 11 at 3:30 PM PT at the Cell & Gene Meeting on the Mesa conference taking place from October 10 to 12 in Carlsbad, California.
Carlsbad, CA
Sep 26, 2023 at 4:55 PM EDT
Helen Sabzevari, PhD, President and CEO, Precigen, participated in a fireside chat on September 26 at 4:55 PM ET at the Cantor Global Healthcare Conference 2023 taking place from September 26 to 28 in New York.
New York, NY
Aug 09, 2023 at 8:30 AM EDT
Precigen quarterly and half year financial results and general business update.
Jun 07, 2023 at 3:15 PM EDT
Rutul Shah, Chief Operating Officer of Precigen, provided a company presentation on Wednesday, June 7, 2023 at 3:15 PM ET.
Boston, Massachusetts
Jun 02 - Jun 06, 2023
- Abstract #2628: Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C). Session Title: Developmental Therapeutics—Immunotherapy. Session Date and Time: June 3, 2023, 8:00 AM-11:00 AM CT.
- Abstract #5590: Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Session Title: Gynecologic Cancer. Session Date and Time: June 5, 2023, 1:15 PM-4:15 PM CT.
May 10, 2023 at 8:00 AM EDT
Precigen quarterly financial results and general business update.
Apr 17, 2023
at 9:00 AM - 12:30 PM EDT
An abstract titled, "Next generation UltraCAR-T® cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity," was presented as a poster presentation.
Apr 04, 2023
at 10:45 AM - 11:15 AM EDT
Helen Sabzevari, PhD, President and CEO of Precigen, participated in a virtual fireside chat.
Apr 04, 2023 at 8:30 AM EDT
Precigen hosted a conference call to provide business and clinical updates for recent announcements.